Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16915737 | 1.00 | OPRM1 (0.51) | OPRM1ALDH1A1SIGMAR1OPRL1FUCA1 | |
| SCHEMBL16926718 | 1.00 | OPRM1 (0.51) | OPRM1ALDH1A1SIGMAR1OPRL1FUCA1 | |
| SCHEMBL16926353 | 1.00 | OPRM1 (0.51) | OPRM1ALDH1A1SIGMAR1OPRL1FUCA1 | |
| SCHEMBL20473610 | 1.00 | OPRM1 (0.51) | OPRM1ALDH1A1SIGMAR1OPRL1FUCA1 | |
| SCHEMBL16915579 | 1.00 | OPRM1 (0.51) | OPRM1ALDH1A1SIGMAR1OPRL1FUCA1 | |
| SCHEMBL14001237 | 0.85 | OPRM1 (0.52) | OPRM1ALDH1A1SIGMAR1OPRL1POLB | |
| SCHEMBL4481641 | 0.81 | OPRL1 (0.54) | ALDH1A1SIGMAR1OPRL1FUCA1POLB | |
| SCHEMBL16659923 | 0.81 | OPRL1 (0.54) | ALDH1A1SIGMAR1OPRL1FUCA1POLB | |
| SCHEMBL14702321 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SIGMAR1OPRL1FUCA1POLB | |
| SCHEMBL5155047 | 0.81 | OPRL1 (0.54) | ALDH1A1SIGMAR1OPRL1FUCA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112625028-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20220348553-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | disclosed |
| US-11401259-B2 | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401259-B2 | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN2 | OPRM1 3840/4885ALDH1A1 3062/4885SIGMAR1 3383/4885 |
| US-20220348553-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN2 | OPRM1 3840/4885ALDH1A1 3062/4885SIGMAR1 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.